Design Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
Design Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares of the Company’s common stock, par value $0.0001 per share (“Stock,” and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
INDEMNITY AGREEMENTIndemnity Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of January 25, 2021, by and among Design Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENTHuman Therapeutics Exclusive License Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Wisconsin
This Human Therapeutics Exclusive License Agreement (“Agreement”) is made effective the 20th day of February, 2019 (“Effective Date”), by and between Wisconsin Alumni Research Foundation (“WARF”), a nonstock, nonprofit Wisconsin corporation, and Design Therapeutics, Inc. (“Licensee”), a corporation organized and existing under the laws of Delaware.
LEASELease • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • California
This Lease (“Lease”) is made and dated as of February 2, 2021 (“Effective Date”), by and between CROSSING HOLDINGS, LLC, a California limited liability company (“Landlord”) and DESIGN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
DESIGN THERAPEUTICS, INC.Offer of Employment • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations
Design Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Executive Chairperson on the terms and conditions set forth in this letter agreement (the “Agreement”).
